<DOC>
	<DOCNO>NCT00511446</DOCNO>
	<brief_summary>Combination regimens 3 active drug show promising activity treatment metastatic gastric cancer . Docetaxel combine cisplatin 5-fluorouracil ( FU ) yield superior overall survival response rate compare standard cisplatin 5-FU . However , toxicity profile show need development less toxic modification . In prior phase I trial , maximum tolerate dose define . In phase II trial , first evaluation activity perform .</brief_summary>
	<brief_title>Trial Docetaxel , Oxaliplatin Capecitabine ( TEX ) Advanced Metastatic Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Written inform consent Histologically proven irresectable , metastatic recurrent adenocarcinoma stomach gastroesophageal junction , i.e. , Tx4 M1 T4 M0 Irresectable ( judge experience surgeon ) : 1 . T4 infiltrate several organ 2 . T4 infiltrate one organ , irresectable 3 . T4 infiltrate one organ , respectable , inoperable patient The nodal status neglect Measurable disease accord RECIST ECOG Performance Status ≤ 2 Male female patient age ≥ 18 year Life expectancy ≥ 3 month Adequate bone marrow , hepatic renal function : 1 . Haemoglobin &gt; 9.0 g/dL ( transfusion allow achieve maintain level ) 2 . Absolute neutrophil count &gt; 1.5 x 10^9/L 3 . Platelet count &gt; 100 x 10^9/L 4 . ALAT , ASAT &lt; 3.5 x ULN 5 . Alkaline phosphatase &lt; 6 x ULN 6 . Total bilirubin &lt; 1.0 x ULN 7 . Creatinine clearance &gt; 50 mL/min ( calculate accord Cockroft Gault ) Prior surgery must 28 day ago Positive node diagnose endorectal ultrasound and/or MRI ( tumour stag preferably high resolution MRI ; MRI available , locoregional staging must perform computed tomography plus endorectal ultrasound ) Tumor stag must do within 28 day start treatment Negative pregnancy test woman childbearing potential ( within 7 day prior start chemotherapy ) Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential Prior cytotoxic chemotherapy radiotherapy ( neoadjuvant adjuvant chemotherapy must complete without progression least 6 month ) Previous ( within last 5 year ) concurrent malignancy , exception adequately treat situ carcinoma cervix basal cell carcinoma skin Peripheral neuropathy ≥ grade 2 ( accord NCI CTCAE v 3.0 ) Patient must treat investigational drug , agent procedure , ( i.e. , participate another trial within 30 day ) entry trial Known allergy adverse reaction study drug relate compound Requirement concurrent use antiviral agent sorivudine ( antiviral ) chemically related analogue , brivudine Clinically significant concomitant disease , : 1 . Active infection necessitate systemic antibiotic 2 . Interstitial lung diseases 3 . Chronic diarrhea , inflammatory bowel disease 4 . Neurological psychiatric disease , dementia , epilepsy untreated brain metastasis Cardiac disease ( e.g. , congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction resuscitation within last 6 month Pregnant lactate woman exclude Presence adequate contraception fertile patient ( method adequate contraception : intrauterine device , hormonal contraception , vasectomy , tubal ligation abstinence ) Alcohol drug abuse Ability swallow tablet Psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Stomach neoplasm</keyword>
	<keyword>docetaxel</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>capecitabine</keyword>
</DOC>